Investigated for treating COVID-19.

Tocilizumab-bavi (Tofidence) is biosimilar to Tocilizumab (Actemra).
Approved 09/29/2023

Tocilizumab-Aazg (Tyenne) is biosimilar to Tocilizumab (Actemra).
Approved 03/05/2024

RISK OF SERIOUS INFECTIONS

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tocilizumab in the treatment of juvenile idiopathic arthritis in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 05/29/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric